Read this article in:
Oxford-based Caristo Diagnostics, a company that specialises in cardiac and vascular disease diagnostics and risk prediction, announced on Monday, April 18, that it has secured £13M (approximately €14.7M) in its Series A financing round.
The company also announced the appointment of Frank Cheng as its new CEO.
The current round was led by Oxford Science Enterprises and joined by BGF, Longwall Venture Partners, Oxford Investment Consultants LLP, Oxford University, and others.
To date, Caristo has raised over £23M (approximately €26M) in venture capital investment.